IN2015DN03909A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03909A
IN2015DN03909A IN3909DEN2015A IN2015DN03909A IN 2015DN03909 A IN2015DN03909 A IN 2015DN03909A IN 3909DEN2015 A IN3909DEN2015 A IN 3909DEN2015A IN 2015DN03909 A IN2015DN03909 A IN 2015DN03909A
Authority
IN
India
Prior art keywords
chloro
methyl
ethyl
amino
human
Prior art date
Application number
Other languages
English (en)
Inventor
Tona M Gilmer
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2015DN03909A publication Critical patent/IN2015DN03909A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
IN3909DEN2015 2012-10-22 2013-10-21 IN2015DN03909A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716780P 2012-10-22 2012-10-22
PCT/US2013/065827 WO2014066202A1 (fr) 2012-10-22 2013-10-21 Combinaison

Publications (1)

Publication Number Publication Date
IN2015DN03909A true IN2015DN03909A (fr) 2015-10-02

Family

ID=50545138

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3909DEN2015 IN2015DN03909A (fr) 2012-10-22 2013-10-21

Country Status (12)

Country Link
US (1) US20150272952A1 (fr)
EP (1) EP2908815A4 (fr)
JP (1) JP2015534986A (fr)
KR (1) KR20150074097A (fr)
CN (1) CN104902899A (fr)
AU (1) AU2013334943A1 (fr)
BR (1) BR112015008924A2 (fr)
CA (1) CA2889051A1 (fr)
IN (1) IN2015DN03909A (fr)
MX (1) MX2015005113A (fr)
RU (1) RU2015119245A (fr)
WO (1) WO2014066202A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
BR112012008271A2 (pt) * 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
WO2011060380A1 (fr) * 2009-11-14 2011-05-19 The Regents Of The University Of California L'état de mutation de pik3ca et l'expression de sash1 prédisent la synergie entre le lapatinib et un inhibiteur d'akt dans le cancer du sein her2 positif
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy

Also Published As

Publication number Publication date
JP2015534986A (ja) 2015-12-07
EP2908815A4 (fr) 2016-06-22
CA2889051A1 (fr) 2014-05-01
WO2014066202A1 (fr) 2014-05-01
US20150272952A1 (en) 2015-10-01
MX2015005113A (es) 2015-10-29
RU2015119245A (ru) 2016-12-10
CN104902899A (zh) 2015-09-09
EP2908815A1 (fr) 2015-08-26
BR112015008924A2 (pt) 2017-07-04
AU2013334943A1 (en) 2015-05-14
KR20150074097A (ko) 2015-07-01

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
PH12016502355A1 (en) Pharmaceutical composition
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MY191357A (en) Sustained-release dosage forms of ruxolitinib
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2013005020A (es) Composiciones y metodos para el tratamiento de la mielofibrosis.
WO2016133903A3 (fr) Polythérapie pour le traitement du cancer
MX2016004936A (es) Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX356704B (es) Combinación.
PH12016502352A1 (en) Pharmaceutical composition
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX359770B (es) Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
TW201129361A (en) Methods for treating pain
IN2015DN03909A (fr)
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.